This article needs additional citations for verification. (December 2009) (Learn how and when to remove this template message)
|AHFS/Drugs.com||International Drug Names|
Propyphenazone/paracetamol/caffeine (trade name Saridon) is an analgesic combination indicated for the management of headache. It contains the analgesics propyphenazone and paracetamol and the stimulant caffeine.
Saridon was first launched by Roche in 1933, initially containing pyrithyldione and phenacetin, widely used remedies for fever and pain. It often contained aspirin, phenacetin and caffeine, but was reformulated in 1981, replacing the original ingredient phenacetin with paracetamol, before phenacetin was banned by the US FDA in 1983. It was available in more than 80 countries across Europe, Latin America, Asia and Africa, but has been discontinued in many of them.
Paracetamol, an analgesic and antipyretic substance, has slow onset but has a longer duration of action and is lacking anti-inflammatory properties. On the other hand, propyphenazone, a non-steroidal anti-inflammatory drug (NSAID), is proven to have a faster onset but shorter duration of action. The combination of paracetamol and propyphenazone increases and prolongs the therapeutic activity of propyphenazone: peak blood plasma concentrations increase by about 40%, and the elimination half-life is prolonged to about 77 minutes. Caffeine, with a stimulating effect, is a drug that wards off drowsiness and restores alertness. It also enhances the analgesic potency of paracetamol, although a Cochrane review concluded that a dose of 100 mg is needed for an effect – double the amount contained in Saridon.
Adverse effects are uncommon and include skin rashes, pruritus (itching), erythema, angioedema, breathing problems such as dyspnea and asthma, anaphylaxis (serious allergic reactions), and decrease in the number of blood cells such as thrombocytopenia, leucopenia, agranulocytosis, and pancytopenia. The latter type of side effect can be severe.
Based on a report from Lareb, a Dutch pharmacovigilance center, it was noted that twenty adverse reactions to Saridon had been reported with no mention of fatal to near fatal cases. The report concluded by saying that there was no information available of the incidence of anaphylactic reactions to propyphenazone, and that the summary of product characteristics (SPC) states an incidence of less than 0.01%. The Lareb report suggests the actual incidence to be higher.
Known interactions are mostly related to the paracetamol component. Barbiturates, phenytoin, carbamazepine and rifampicin increase the formation of toxic paracetamol metabolites in the liver. Alcohol also increases paracetamol's liver toxicity. The combination of zidovudine with paracetamol can increase the risk of neutropenia. Elimination of chloramphenicol is prolonged five-fold by paracetamol.
Contraindications are hypersensitivity to phenazone, propyphenazone, aminophenazone, metamizol, phenylbutazone, paracetamol, acetylsalicylic acid, or caffeine; bone marrow deficiencies; glucose-6-phosphate dehydrogenase deficiency; acute hepatic porphyria; alcoholism; gastrointestinal ulcera or bleeding; pregnancy and lactation; infants and children under 6 to 12 years (varying by country).
Society and culture
WHO comment: "Propyphenazone, a pyrazolone derivative with anti-inflammatory, analgesic and antipyretic activity, was introduced in 1951 for the treatment of rheumatic disorders. As it is structurally related to aminophenazone it has been associated with severe blood dyscrasias. However, it cannot be transformed into potentially carcinogenic nitrosamines and has therefore been widely used as a replacement drug for aminophenazone. In certain countries, products containing propyphenazone have now been restricted in their indications, whereas in others they are still available, sometimes as over-the-counter preparations."
- “SEOUL - Amid rising claims that it isn't moving fast enough to counter public concern over the safety of OTC painkillers, Korea FDA has banned Bayer Korea's painkiller Saridon-A, Samjin Pharm's Geworin and 26 other products from being prescribed or sold over the counter to those under 15 years of age”
- Turkey: Banned for production and sale in January 1986 because of severe adverse reactions.
In India, Saridon is made available by Piramal Enterprises Ltd. Mostly used by common man to get relief from headache. Saridon is available at ₹ 24.10 (as of November 2016) per a strip which contains 10 tablets.
Saridon is available in the Philippines and is being sold at a suggested retail price of PhP4.35 per tablet. Initially available in the Visayas-Mindanao region only, it was rolled out in Luzon in 2011 with the goal of replicating its success in Visayas and Mindanao in a national scope.
Saridon is the only pain medication in the country that has three active ingredients, and the only one listing caffeine as one of its ingredients.
Saridon is not found in the Singapore market anymore. In an old copy of DIMS, it was listed that it contained propyphenazone 150 mg, ethoxybenzamide[clarification needed] 250 mg, pyrithyldione 50 mg, and caffeine 50 mg.
- Voelker, Michael & Petersen, Birte. (2009). “Saridon Summary of Clinical Overview”. 1-3.
- Jentzsch, A, ed. (1998). Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag.
- McKay, Gerard A.; Walters, Matthew R. (2013). "Non-Opioid Analgesics". Lecture Notes Clinical Pharmacology and Therapeutics (9th ed.). Hoboken: Wiley. ISBN 9781118344897.
- Derry, C. J.; Derry, S; Moore, R. A. (2014). "Caffeine as an analgesic adjuvant for acute pain in adults". The Cochrane database of systematic reviews (12): CD009281. doi:10.1002/14651858.CD009281.pub3. PMID 25502052.
- Consolidated List of Products whose Consumption and/or Sale have been Banned, Withdrawn, Severely Restricted or not Approved by Governments, Twelfth Issue (pdf). New York: Department of Economic and Social Affairs of the United Nations Secretariat. 2005. p. 232.
- Mediq.ch: Interaction check. Accessed 16 February 2017.
- Consolidated List of Products Whose Consumption And/Or Sale Have Been Banned Withdrawn Severely Restricted Or Not Approved By Governments Twelfth Issue, Published by the Department of Economic and Social Affairs of the United Nations Secretariat Copyright 2005 New York Page 232 Retrieved on 28 October 2012 
- Multi-Country Survey On Banned And Restricted Pharmaceuticals, Health Action International Asia Pacific August 2008, page 7, Retrieved on 28 October 2012
- Bayer’s Saridon-A Among 28 Painkillers Banned To Those Under 15 In Korea, PharmAsia News March 12, 2009; Retrieved on 28 October 2012 
- "Saridon tvc". YouTube. 2011-07-06. Retrieved 2012-07-24.
- Singapore HSA checked on 07/09/2016.
- Singapore DIMS Annual 1990 page 669.